Novo Nordisk sues Hims & Hers over ‘knock-off Wegovy’

Novo Nordisk has filed suit against telemedicine provider Hims & Hers, alleging patent infringement by marketing and selling compounded semaglutide products marketed as copies of Ozempic and Wegovy and asking a federal court to declare infringement, permanently enjoin sales and award damages. The complaint stresses patient-safety and regulatory concerns after a multiyear semaglutide shortage ended in October 2024, notes Novo’s prior commercial partnerships with telemedicine providers that dissolved when compounded sales continued, and highlights potential revenue and market-share implications for Hims & Hers if sales are blocked while reinforcing Novo’s IP protections.

Analysis

Market structure: Novo Nordisk (NVO) is the clear near-term beneficiary as a successful suit would blunt competing compounded semaglutide supply and defend branded pricing/margin power; Eli Lilly (LLY) and other GLP‑1 innovators also benefit from reduced downward pricing pressure. Direct losers are Hims & Hers (HIMS) and compounding-focused players whose revenue/GM exposure to GLP‑1s could face an immediate legal shutdown; expect elevated implied volatility and potential equity drawdowns of 20–50% for exposed telemedicine/compounders if injunctions follow. Cross-asset: HIMS credit spreads and equity vols should widen; NVO credit impact immaterial but modest positive for Danish krona (DKK) sentiment and for large-cap pharma equities.

Risk assessment: Tail risks include a plaintiff loss or regulatory guidance favoring compounding that permanently commoditizes semaglutide, which could erode NVO pricing by an outsized 10–30% over years. Timing: expect headline volatility in days, court motions/preliminary injunction news within 30–90 days, and definitive rulings in 6–18 months; long-term patent and biosimilar pressure plays out over multiple years. Hidden dependencies include API sourcing and pharmacy litigation spillovers; catalysts are preliminary injunction rulings, FDA statements, and settlement/royalty deals.

Trade implications: Direct actionable plays are long NVO (6–12 month horizon) and short HIMS (3–6 month horizon); prefer defined‑risk option structures — buy HIMS 3‑month puts (30–45 delta) or 3‑month put spreads, and NVO 9–12 month call spreads 5–10% OTM to limit capital. Relative value: pair trade long NVO / short HIMS equal dollar exposure; rotate into large-cap biotech (NVO, LLY) and trim telemedicine/compounding small caps by 30–50% of benchmark weight. Entry/exit: initiate within next 2–10 trading days on sustained headlines; set stop-losses at 15–20% adverse move and trim 50% on 30% realized move.

Contrarian angles: Consensus underestimates settlement/licensing outcomes — pharma historically prefers negotiated licenses that cap upside of an NVO surge and limit HIMS downside if compensated. Historical parallels (big pharma vs. compounding fights) often end in licensing or narrow injunctions rather than industrywide bans, so NVO upside may be capped to single‑digit earnings beat; conversely, HIMS may recover if settlements restore partial supply channels. Monitor court docket and any FDA enforcement memos over the next 30–90 days for asymmetric information events.

Key Decisions for Investors

• Establish a 2–3% long position in NVO (Novo Nordisk) with a 6–12 month horizon; hedge with a 9–12 month 5–10% OTM call spread to size upside while limiting capital risk.
• Initiate a 2% short exposure to HIMS (Hims & Hers) via 3‑month put spreads (30–45 delta buys, 10–15% OTM) targeting 30–50% downside within 3–6 months; set stop-loss at a 20% adverse move.
• Implement a pair trade: long NVO (equal dollar) / short HIMS (equal dollar) sized to 3–4% net portfolio exposure to capture relative enforcement outcomes; close or rebalance on a 25–30% move in either leg.
• Reduce benchmark weight in telemedicine/compounding-exposed small caps by 30–50% and rotate into large-cap GLP‑1 beneficiaries (NVO, LLY) over next 30 days as litigation risk clears.
• Monitor three triggers for position adjustments: (1) preliminary injunction decision within 30–90 days, (2) FDA enforcement or guidance within 60 days, (3) any announced settlement/licensing — act to close HIMS shorts and materially trim NVO longs if a broad licensing deal is confirmed.